We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

101 hedge funds and large institutions have $526M invested in Collegium Pharmaceutical in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 39 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

371% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 7

179% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 14

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

93% more capital invested

Capital invested by funds: $273M → $526M (+$253M)

35% more funds holding

Funds holding: 75101 (+26)

0.53% less ownership

Funds ownership: 88.06%87.53% (-0.53%)

53% less call options, than puts

Call options by funds: $622K | Put options by funds: $1.34M

Holders
101
Holders Change
+26
Holders Change %
+34.67%
% of All Funds
2.29%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
33
Increased
39
Reduced
14
Closed
7
Calls
$622K
Puts
$1.34M
Net Calls
-$715K
Net Calls Change
-$209K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$4.14M +$1.71M +119,640 +114%
NIP
27
Nicholas Investment Partners
California
$3.62M +$2.81M +196,093 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$3.54M +$209K +14,589 +8%
CIP
29
Chartwell Investment Partners
Pennsylvania
$3.4M +$2.64M +184,337 New
MCM
30
Moore Capital Management
New York
$3.23M +$1.79M +125,000 +250%
LPL Financial
31
LPL Financial
California
$2.79M +$130K +9,082 +6%
UBS Group
32
UBS Group
Switzerland
$2.78M +$2M +139,824 +1,279%
NCGI
33
Next Century Growth Investors
Minnesota
$2.68M +$2.08M +144,972 New
FHAM
34
Folger Hill Asset Management
New York
$2.58M +$2.01M +140,000 New
RA
35
Royce & Associates
New York
$2.53M +$1.96M +137,000 New
Renaissance Technologies
36
Renaissance Technologies
New York
$2.42M +$1.87M +130,800 New
Goldman Sachs
37
Goldman Sachs
New York
$2.07M +$456K +31,807 +40%
BGIM
38
Brandywine Global Investment Management
Pennsylvania
$1.95M -$166K -11,623 -10%
ARTA
39
A.R.T. Advisors
New York
$1.62M +$967K +67,500 +333%
GIP
40
Granite Investment Partners
California
$1.29M +$255K +17,784 +34%
NC
41
NBW Capital
Massachusetts
$1.27M -$16.2K -1,128 -2%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$1.24M +$593K +41,414 +163%
TA
43
Teachers Advisors
New York
$1.23M +$96.5K +6,739 +11%
Millennium Management
44
Millennium Management
New York
$1.22M -$15.8M -1,106,580 -94%
T. Rowe Price Associates
45
T. Rowe Price Associates
Maryland
$1.18M +$914K +63,807 New
Two Sigma Investments
46
Two Sigma Investments
New York
$1.18M +$913K +63,723 New
TCIM
47
TIAA CREF Investment Management
New York
$1.1M +$4.03K +281 +0.5%
Charles Schwab
48
Charles Schwab
California
$944K +$87.1K +6,083 +14%
JG
49
Jefferies Group
New York
$893K +$693K +48,400 New
JP Morgan Chase
50
JP Morgan Chase
New York
$848K +$394K +27,516 +149%

COLL Hedge Fund Activity: Q4 2017 in Review

101 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2017, worth a combined $526M — up 93% from $273M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new COLL positions and 7 closed out — a net gain of 26 holders — while 39 added to existing stakes and 14 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $47.2M. The largest seller was Cadian Capital Management, exiting entirely with an estimated $21.6M sold.

  • 101 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2017, up from 75 in Q3 2017.
  • Funds reported $526M of Collegium Pharmaceutical stock for Q4 2017, up 93% quarter-over-quarter.
  • 33 funds opened new Collegium Pharmaceutical positions in Q4 2017 and 7 closed out, a net change of +26 holders.
  • The largest Collegium Pharmaceutical buyer in Q4 2017 was Janus Henderson Group, an estimated $47.2M added.
  • The largest Collegium Pharmaceutical seller in Q4 2017 was Cadian Capital Management, an estimated $21.6M sold.

Based on aggregated 13F filings for Q4 2017.